Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23581583.
- Also identified by DOI 10.3171/2013.3.JNS122282 and PMC identifier 3672384.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered to be frequent and highly conserved in secondary glioblastoma multiforme and lower-grade gliomas. Although IDH1 mutations confer a unique genotype that has been associated with a favorable prognosis, the role of the mutated IDH1 enzyme and its metabolites in tumor initiation and maintenance remains unresolved. However, given that IDH1 mutations are homogeneously expressed and are limited solely to tumor tissue, targeting this mutation could potentially yield novel treatment strategies for patients with glioblastoma multiforme.
Medical subject headings
- Brain Neoplasms
- Glioblastoma
- Glioma
- Isocitrate Dehydrogenase
- Mutation